aibioCelularity gets Nasdaq notice on market value of listed securities, has until December 7, 2026
Tickers CELU
Nasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.
Key facts
- Company
- Celularity Inc. (NASDAQ: CELU)
- News type
- Listings
- Primary source
- Celularity Inc Form 8-K filed June 12, 2026 (SEC EDGAR)
Celularity Inc said on June 12, 2026 that it has received a Nasdaq deficiency notice because the market value of its listed securities has been below the minimum for continued listing on The Nasdaq Capital Market. The company disclosed the notice in a Form 8-K under Item 3.01. The notice does not delist the stock, and Celularity has until December 7, 2026 to regain compliance.
What the Nasdaq notice says
On June 9, 2026, Celularity received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq"). The Staff said that for the last 30 consecutive business days before the date of the notice, the company's minimum Market Value of Listed Securities was below the $35 million required for continued listing on The Nasdaq Capital Market. The requirement comes from Nasdaq Listing Rule 5550(b)(2), which the filing calls the MVLS Requirement.
Under Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq gave the company 180 calendar days, or until December 7, 2026, which the filing calls the Compliance Date. If Celularity regains compliance, Nasdaq will provide written confirmation to the company and close the matter. The filing states that the notice does not result in the delisting of the company's common stock from The Nasdaq Capital Market.
How the company can regain compliance
To regain compliance, the market value of Celularity's common stock must meet or exceed $35.0 million for a minimum of 10 consecutive business days during the 180-day grace period that ends on the Compliance Date. The Staff may use its discretion to extend that period of ten consecutive business days under Nasdaq Listing Rule 5810(c)(3)(H).
The 10-K says that as of December 31, 2025 the company had limited cash and cash equivalents and continued to incur significant operating losses and negative operating cash flows, and that its current revenues are not sufficient to fund operating expenses, debt service and working capital needs. It also says Celularity has no cellular therapeutics approved for commercial sales. Celularity says it is evaluating potential actions to regain compliance and intends to actively monitor the market value of its listed securities. It also says it may, if appropriate, consider other options to meet Nasdaq's continued listing standard, such as increasing its stockholders' equity to at least $2.5 million.
If the deadline passes
If Celularity does not regain compliance before the Compliance Date, it will receive written notification that its securities are subject to delisting. At that point the company may appeal the delisting determination.
About the company
Celularity's annual report on Form 10-K, filed April 30, 2026, describes the business. The company calls itself a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease. Its therapies are derived from the post-partum human placenta. The report says the objective of extending health longevity is to reduce the duration and severity of aging-related degenerative diseases and disorders that are associated with increased mortality toward the end of life.
Losses, cash and restructuring
The financial figures in the 10-K show revenue of $26.6 million for 2025, against $54.2 million for 2024. Celularity reported a net loss of $91.7 million for 2025, against $57.9 million for 2024, and cash used in operations of $13.3 million, against $6.4 million. Cash and cash equivalents were $738,000 at the end of 2024.
The 10-K's risk factors say the company has little cash on hand and does not generate sufficient cash from operations to operate for the next twelve months. It says it needs to raise additional cash through equity or debt sales and that, if it does not, it will not be able to continue as a going concern. It also says that in the first quarter of 2026 it reduced headcount and salaries to restructure its business. John Sprague, Chief Financial Officer, signed the Form 8-K, and the 8-K gives no figure for the market value of the company's listed securities.